Literature DB >> 9226154

Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells.

A A Cardoso1, M J Seamon, H M Afonso, P Ghia, V A Boussiotis, G J Freeman, J G Gribben, S E Sallan, L M Nadler.   

Abstract

In contrast to other neoplasms, antigen-specific autologous cytolytic T cells have not been detected in patients with human pre-B-cell leukemias. The absence of efficient B7 family (B7-1/CD80; B7-2/CD86) -mediated costimulation has been shown to be a major defect in tumor cells' capacity to function as antigen-presenting cells. We show here the generation of autologous anti-pre-B-cell leukemia-specific cytolytic T-cell lines from the marrows of 10 of 15 patients with pre-B-cell malignancies. T-cell costimulation via CD28 is an absolute requirement for the generation of these autologous cytolytic T cells (CTL). Although costimulation could be delivered by either bystander B7 transfectants or professional antigen-presenting cells (indirect costimulation), optimal priming and CTL expansion required that the costimulatory signal was expressed by the tumor cell (direct costimulation). These anti-pre-B-cell leukemia-specific CTL lysed both unstimulated and CD40-stimulated tumor cells from each patient studied but did not lyse either K562 or CD40-stimulated allogeneic B cells. Cytolysis was mediated by the induction of tumor cell apoptosis by CD8+ T cells via the perforin-granzyme pathway. Although we were able to generate anti-leukemia-specific CTL from the bone marrow, we were unable to generate such CTL from the peripheral blood of these patients. These studies show that antigen-specific CTL can be generated from the bone marrow of patients with pre-B-cell leukemias and these findings should facilitate the design of adoptive T-cell-mediated immunotherapy trials for the treatment of patients with B-cell precursor malignancies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226154

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Enhancement of cALL immunogenicity by co-culture with a CD154 expressing 293 cell line.

Authors:  A J Lee; C Haworth; R M Hutchinson; R Patel; R Carter; R F James
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Cross talk between CD3 and CD28 is spatially modulated by protein lateral mobility.

Authors:  Keenan T Bashour; Jones Tsai; Keyue Shen; Joung-Hyun Lee; Eileen Sun; Michael C Milone; Michael L Dustin; Lance C Kam
Journal:  Mol Cell Biol       Date:  2013-12-30       Impact factor: 4.272

3.  Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.

Authors:  Fatma Visal Okur; Eric Yvon; Ettore Biagi; Gianpietro Dotti; George Carrum; Helen Heslop; Martha P Mims; Joseph C Fratantoni; Madhusudan V Peshwa; Linhong Li; Malcolm K Brenner
Journal:  Cytotherapy       Date:  2011-07-12       Impact factor: 5.414

4.  Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.

Authors:  W Nicholas Haining; Donna S Neuberg; Heather L Keczkemethy; John W Evans; Stephen Rivoli; Rebecca Gelman; Howard M Rosenblatt; William T Shearer; Javier Guenaga; Daniel C Douek; Lewis B Silverman; Stephen E Sallan; Eva C Guinan; Lee M Nadler
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

5.  Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.

Authors:  J K Orleans-Lindsay; L D Barber; H G Prentice; M W Lowdell
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

6.  Induction of abortive and productive proliferation in resting human T lymphocytes via CD3 and CD28.

Authors:  Y Müller; H Wolf; E Wierenga; G Jung
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

7.  Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.

Authors:  Raphaël F Rousseau; Ettore Biagi; Aurélie Dutour; Eric S Yvon; Michael P Brown; Tiffany Lin; Zhuyong Mei; Bambi Grilley; Edwina Popek; Helen E Heslop; Adrian P Gee; Robert A Krance; Uday Popat; George Carrum; Judith F Margolin; Malcolm K Brenner
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

Review 8.  Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice.

Authors:  Michael R Verneris; Jeanette Baker; Matthias Edinger; Robert S Negrin
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317

Review 9.  Immunotherapy in acute leukemia.

Authors:  Wing Leung
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 10.  [Immunmodulatory antibodies in the treatment of skin cancer].

Authors:  D Schrama; A Hauschild; J C Becker
Journal:  Hautarzt       Date:  2008-10       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.